NCT05411887Active, not recruiting
Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
A Non-interventional, Multi Center, Prospective Observational Study to Evaluate the Effect of Improving Systolic Blood Pressure and Low-density Lipoprotein Cholesterol Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab. in Patients With Essential Hypertension and Dyslipidemia.
Source: ClinicalTrials.gov · Last updated 24 Aug 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate variables that affect treatment effectiveness.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 2845 (actual)
- First submitted
- 19 May 2022
- Start date
- 20 Jun 2022
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Diseases
- High blood pressure
- NCT number
- NCT05411887
What you commit to
- Study type: Observational
- Participants enrolled: 2845
- From 20 Jun 2022 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A person who has been administered the study target drug or is being administered at the time of recruitment within 6 months based on the date of the study contract
Other
- A person who falls under "2. Do not administer to the following patients" among the precautions for use in the user manual
- Patients in hospital (hospitals only; nursing care facilities can be recruited)
Who the study is looking for
- men and women over the age of 19
- Patients who signed a written consent form to participate in the study
- Patients who are eligible for Olostar tablet prescription according to domestic permission
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Severance hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.